Practical implication
MAHs and sponsors must review and potentially update internal SOPs and reporting forms that currently reference 'gender' to ensure compliance with the updated terminology and definitions.
The FDA announced it is reopening the comment period for a proposed rule aimed at modifying terminology in Title 21 of the CFR, specifically to replace instances of the term 'gender' with 'sex' or remove the term entirely. This update aligns with Executive Order 14168 and impacts regulations regarding patient demographics, particularly in safety reporting and clinical trial data collection. Stakeholders have until October 2, 2026, to submit comments.
What changed: The FDA is reopening the comment period for public input on the proposed rule for an additional 60 days, ending on October 2, 2026.
Why it matters: This change is significant as it alters the regulatory definitions for demographic data in multiple regulations, thus impacting how data is reported and collected in the context of human and veterinary drugs, biologics, and devices.
Practical implication: MAHs and sponsors must review and potentially update internal SOPs and reporting forms that currently reference 'gender' to ensure compliance with the updated terminology and definitions.
View original source
Published from the Firecrawl policy change extraction pipeline.
